Teva CEO Vigodman Reveals A First Glimpse At His Strategy

Teva’s new CEO addressed investors publicly for the first time May 1 and discussed his initial thoughts on plans to turn around the generic drug leader. Those include deeper cost cuts, a renewed emphasis on generic drugs and biosimilars, and potentially a large acquisition.